Clinicopathological Features in Bilateral Breast Cancer

  • Baykara, Meltem ;
  • Ozturk, Selcuk Cemil ;
  • Buyukberber, Suleyman ;
  • Helvaci, Kaan ;
  • Ozdemir, Nuriye ;
  • Alkis, Necati ;
  • Berk, Veli ;
  • Koca, Dogan ;
  • Coskun, Ugur ;
  • Oksuzoglu, Berna ;
  • Uncu, Dogan ;
  • Arpaci, Erkan ;
  • Ustaalioglu, Basak Oven ;
  • Demirci, Umut ;
  • Kucukoner, Mehmet ;
  • Dogu, Gamze Gokoz ;
  • Alici, Suleyman ;
  • Akman, Tulay ;
  • Ozkan, Metin ;
  • Aslan, Ulku Yalcintas ;
  • Durnali, Ayse Gok ;
  • Benekli, Mustafa
  • Published : 2012.09.30


Introduction and Purpose: The frequency of bilateral breast cancer is 1.4-11.0% among all breast cancers. It can present as synchronous (SC) or metachronous (MC). Data regarding clinical course of bilateral breast cancer are scarce. In this study, we therefore evaluated demographic, pathological and clinical characteristics, treatments and responses in bilateral breast cancer cases; making distinctions between metachronous-synchronous and comparing with historic one-sided data for the same parameters. Materials and Methods: One hundred fifty bilateral breast cancer cases from ten different centers between 2000 and 2011 were retrospectively scanned. Age of the cases, family history, menopausal status, pathological features, pathological stages, neoadjuvant, surgery, adjuvant and palliative chemotherapy/radiotherapy were examined in the context of the first and second occurrence and discussed with reference to the literature. Results: Metachronous and synchronous groups showed similar age, menopausal status, tumor type, HER2/neu expression; the family history tumor grade, tumor stage, ER-negativity rate, local and distant metastases rates, surgery, adjuvant chemotherapy application rates were identified as significantly different. Palliative chemotherapy response rate was greater in the metachronous group but median PFS rates did not differ between the groups. Conclusion: Although bilateral breast cancer is not frequent, MC breast cancer is different from SC breast cancer by having more advanced grade, stage, less ER expression, more frequent rates of local relapse and distant metastasis and better response to chemotherapy in case of relapse/metastasis.


Bilateral breast cancer;synchronous;metachronous;clinicopathological characteristics;Turkey


  1. Beckmann KR, Buckingham J, Craft P, Dahistrom JE (2001). Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort. The Breast, 20, 158-64.
  2. Berry DA, Cirrincione C, Henderson IC, et al (2006). Estrogen- Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA, 29, 1658-67.
  3. Chaudary MA, Millis RR, Hoskins EO, et al (1984). Bilateral primary breast cancer:a prospective study of disease incidence. Br J Surg, 71, 711-4.
  4. Donovan AJ (1990). Bilateral breast cancer. Surg Clin N Am, 70, 1141-9.
  5. Gogas J, Markopulos C, Skandalakis P, Gogan H (1993). Bilateral breast cancer. Am Surg, 59, 733-5.
  6. Gollamudi SV, Gelman RS, Peiro G, et al (1997). Breast conserving therapy for stage I-II synchronous bilateral breast carcinoma. Cancer, 79, 1362-9.<1362::AID-CNCR14>3.0.CO;2-Y
  7. Hartman M, Czene K, Reilly M, et al (2007). Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol, 25, 4210-6.
  8. Heron DE, Komarnicky LT, Hyslop T, Shwartz GT, Mansfiel CM (2000). Bilateral breast carcinoma: risk factors and outcomes for patient with synchronous and metachronous dissease. Cancer, 88, 2739-50.<2739::AID-CNCR12>3.0.CO;2-J
  9. Huo D, Melkonian S, Rathouz PJ, Khramtsov A, Olopade OI (2011). Concordance in histological and biological parameters between first and second primary breast cancer. Cancer, 117, 907-15.
  10. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics. CA Cancer J Clin, 60, 277.
  11. Kheirelseid EA, Jumustafa H, Miller N, et al (2011). Bilateral breast cancer: analysis of incidence, outcome, survival and dissease characteristics. Breast Cancer Res Treat, 126, 131-40.
  12. Michowitz M, Noy S, Lazebnik N, Aladjem D (1985). Bilateral breast cancer. J Surg Oncol, 30, 109-12.
  13. Mersheimer WL, Black MM, Chabon AD (1965). The second breast. N Y State J Med, 65, 2460-8.
  14. Polednak AP (2003). Bilateral synchronous breast cancer: a population based study of characteristics, method and detection and survival. Surgery, 133, 383-9.
  15. Slamon DJ, Godolphin W, Jones LA, et al (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 4905, 707-12.
  16. Takahashi H, Watanabe K, Takahashi M, et al (2005). The impact of bilateral breast cancer on the prognosis of breast cancer:a comparative study with unilateral breast cancer. Breast Cancer, 12, 196-02.
  17. Turnbull C, Rahman N (2008). Genetic predisposition to breast cancer:past,present and future. Annu Rev Genomics Hum Genet, 9, 321-45.
  18. Verkooijen HM, Chatelain V, Fioretta G, et al (2007). Survival after bilateral breast cancer: results from population-based study. Breast Cancer Res Treat, 105, 347-57.
  19. Vuoto HD, García AM, Candás GB, et al (2010). Bilateral breast carcinoma: Clinical characteristics and its impact on survival. Breast J, 16, 625-32.

Cited by

  1. Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pair-matched immunohistochemical analysis aimed at intrinsic tumor phenotype vol.64, pp.10, 2014,
  2. Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up vol.16, pp.12, 2015,
  3. Impact of Bilateral Breast Cancer on Prognosis: Synchronous Versus Metachronous Tumors vol.16, pp.3, 2015,